Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT10109L for Glabellar and Lateral Canthal Lines
NCT03721016Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of nivolumab + botulinumtoxinA in glabellar lines and lateral canthal rhytides (3 arms), sponsored by Medytox Inc. Primary endpoint: Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) at Day 30. Started Oct 2018; status: completed.
02
Drugs
nivolumab + botulinumtoxinA
03
Conditions
glabellar lineslateral canthal rhytides
Beyond the preview
Go deeper on NCT03721016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721016.